• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Signal detection of adverse events associated with gabapentinoid use for chronic pain
CONCLUSIONS: Our study identified expected and unexpected ADE signals in GABA users. Neurological signals likely related to indications for GABA use. Signals for immunity, mental/behavior, and skin disorders were found in the FDA adverse event reporting system database. Unexpected signals of stroke and cancer require further confirmatory analyses to verify.PMID:37640024 | DOI:10.1002/pds.5685
Source: Cancer Control - August 28, 2023 Category: Cancer & Oncology Authors: Yong-Fang Kuo Efstathia Polychronopoulou Mukaila A Raji Source Type: research

U.S. FDA Approves TECVAYLI ™ (teclistamab-cqyv), the First Bispecific T-cell Engager Antibody for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
HORSHAM, Pa., October 25, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) approved TECVAYLI™ (teclistamab-cqyv) for the treatment of adult patients with relapsed or refractory multiple myeloma, who previously received four or more prior lines of therapy, including a proteasome inhibitor, immunomodulatory drug and anti-CD38 monoclonal antibody.1 TECVAYLI™ is a first-in-class, bispecific T-cell engager antibody that is administered as a subcutaneous treatment.1 This off-the-shelf (or ready to use) therapy uses innovative science to ac...
Source: Johnson and Johnson - October 25, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen to Present the Strength and Promise of its Hematologic Malignancies Portfolio and Pipeline at ASH 2021
RARITAN, N.J., November 4, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 45 company-sponsored abstracts, including 11 oral presentations, plus more than 35 investigator-initiated studies will be featured at the American Society of Hematology (ASH) Annual Meeting and Exposition. ASH is taking place at the Georgia World Congress Center in Atlanta and virtually from December 11-14, 2021.“We are committed to advancing the science and treatment of hematologic malignancies and look forward to presenting the latest research from our robust portfolio and pipeline during ASH...
Source: Johnson and Johnson - November 5, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Palliative Care Clinicians Caring for Patients Before and After Continuous Flow-Left Ventricular Assist Device
Left ventricular assist devices (LVADs) are an available treatment option for carefully-selected patients with advanced heart failure. Initially developed as a bridge to transplantation, LVADs are now also offered to patients ineligible for transplantation as destination therapy (DT). Individuals with a DT-LVAD will live the remainder of their lives with the device in place. While survival and quality of life improve with LVADs compared to medical therapy, complications persist including bleeding, infection, and stroke.
Source: Journal of Pain and Symptom Management - July 12, 2017 Category: Palliative Care Authors: Sara E. Wordingham, Colleen K. McIlvennan, Timothy J. Fendler, Amy L. Behnken, Shannon M. Dunlay, James N. Kirkpatrick, Keith M. Swetz Source Type: research

Hospice and Palliative Medicine Clinician Views of Deactivation of Ventricular Assist Devices at End of Life
Left ventricular assist devices (LVADs) provide circulatory support to patients with advanced heart failure. These devices are used as a temporary bridge to recovery, bridge to cardiac transplantation, or as destination therapy (DT)—where the patient will have the device in situ for the remainder of his/her life. Compared to medical management alone, LVAD-DT often improves survival and quality of life for patients with severe heart failure.1 However, patients with LVADs may experience a host of challenges including a catastrophic event (e.g., stroke, hemorrhage, infection), a concurrent slow decline in health (e.g., righ...
Source: Journal of Pain and Symptom Management - May 26, 2015 Category: Palliative Care Authors: Keith M. Swetz, Sara E. Wordingham, Matthew H. Armstrong, Katlyn E. Koepp, Abigale L. Ottenberg Source Type: research

Hospice and Palliative Medicine Clinician Views of Deactivation of Ventricular Assist Devices at the End of Life
Left ventricular assist devices (LVADs) provide circulatory support to patients with advanced heart failure. These devices are used as a temporary bridge to recovery, bridge to cardiac transplantation, or as destination therapy (DT)—where the patient will have the device in situ for the remainder of his/her life. Compared to medical management alone, LVAD-DT often improves survival and quality of life for patients with severe heart failure.1 However, patients with LVADs may experience a host of challenges including a catastrophic event (e.g., stroke, hemorrhage, infection), a concurrent slow decline in health (e.g., righ...
Source: Journal of Pain and Symptom Management - May 26, 2015 Category: Palliative Care Authors: Keith M. Swetz, Sara E. Wordingham, Matthew H. Armstrong, Katlyn E. Koepp, Abigale L. Ottenberg Tags: Letter Source Type: research